All News

Results from the phase 3 BRUIN CLL-313 trial show that OS trended favorably for pirtobrutinib vs chemoimmunotherapy in this CLL and SLL population.

Subgroup data from KEYNOTE-671 support the use of perioperative pembrolizumab in stage II or III non–small cell lung cancer of any clinical nodal status.

AE-related discontinuations of osimertinib were low, and no new treatment-related deaths were reported with the combination in EGFR-mutant NSCLC.

Sundar Jagannath, MBBS, said that when a cure is defined for patients with multiple myeloma, specific patients may be able to stop therapy without a risk of relapsing.

Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Results from the phase 1b/2 CARTITUDE-1 trial showed that after patients receiving cilta-cel were disease-free for 5 years, they did not need maintenance therapy.

Trastuzumab pamirtecan’s developers plan to discuss next steps regarding a submission of a biologics license application for this breast cancer population.

Hydration and a healthy, well-balanced diet may mitigate fatigue among patients undergoing treatment for cancer.

The medical characteristics of a patient may heavily factor into the selection of tyrosine kinase inhibition for the treatment of chronic myeloid leukemia.

The performance of the latest Shield algorithm underwent validation in an expanded cohort of individuals enrolled on the ECLIPSE study.

Bland foods, such as crackers and chicken noodle soup, as well as fluids with electrolytes may help stave off treatment-related nausea.

The toxicity profile of interferon and the limited availability of transplantation established a need for TKI development for chronic myeloid leukemia.

The safety and cytokine release syndrome profiles of mosunetuzumab were manageable in patients with previously untreated marginal zone lymphoma.

Changes in FKSI-15 scores from baseline indicated more favorable HRQOL outcomes with the benmelstobart combo vs sunitinib in advanced ccRCC.

The approach to treating patients with multiple myeloma will change for physicians, pharmaceutical companies, and even patients themselves.

Data from the AQUILA trial support early intervention with fixed-duration subcutaneous daratumumab for those with high-risk smoldering multiple myeloma.

Predictors of response have a significant effect on clinical decision-making because they may help oncologists select the best treatment for specific patients.

According to Denise B. Reynolds, RD, patients eating well should not be experiencing nutritional deficiencies during cancer treatment.

Data from a propensity-matched analysis showed that GLP-1 receptor agonists conferred benefits even among patients with type 2 diabetes.

Delaying treatment with ruxolitinib by more than a year leads to decreased response rates and overall survival in patients with myelofibrosis.

The modified overall response rate was higher with venetoclax/azacitidine vs placebo/azacitidine in patients with intermediate/high risk MDS.

Patients with recurrent or metastatic cervical cancer in Hong Kong are now eligible to receive treatment with tisotumab vedotin.

Referrals to dietitians may help in the management of TEAEs affecting taste and smell, as well as fatigue in patients undergoing cancer treatment.

Results from the phase 3 MIRASOL trial led to the approval of mirvetuximab soravtansine for patients with FRα+ ovarian cancer.

Results from the Beamion-LUNG 1 trial showed an ORR of 75% for patients with HER2+ NSCLC treated with zongertinib.

In patients with rectal cancer, the median OS was 12 years in the chemotherapy and radiation therapy group vs 24 years in the chemotherapy alone group.

Researchers from the BMT CTN reported that posttransplant cyclophosphamide-based GVHD prophylaxis significantly improves outcomes for adults aged 70 years and older undergoing allo-HCT.

Researchers at the CHOP have developed a new strategy to improve the effectiveness of GPC2-directed CAR T-cell therapy in neuroblastoma by reprogramming the tumor immune microenvironment.

Results from a phase 2 trial showed a 1-year local control rate of 93.1% with SABR in patients with solid tumors who have uncomplicated bone metastases.

External validation will be assessed in cohort 2 of the AURORAX-0087A trial to improve recurrence detection for clear cell renal cell carcinoma.